UK trial to test ADHD and diabetes drugs in 1,200 people with Alzheimer’s
A UK trial will test existing medicines, including the ADHD drug atomoxetine, to see whether they can ease symptoms or slow processes linked to Alzheimer’s disease. Its multi-drug design aims to speed up treatment research, which matters because current trials can take many years to show whether a medicine works.
The Ad-Smart trial will start with atomoxetine and the type 2 diabetes drug metformin, comparing them with a shared placebo group. It aims to recruit 1,200 people across up to 20 NHS sites over the next 18 months, with initial results expected by 2030; researchers will track participants using regular scans and blood tests. Alzheimer’s affects around 600,000 people in the UK.
In short
- UK researchers will test atomoxetine and metformin in Alzheimer’s patients.
- Ad-Smart aims to recruit 1,200 people at up to 20 NHS sites.
- Researchers hope the trial design will speed up treatment testing.
Read the full article at the source →
Originally published by Daily Mail as “Hundreds of Alzheimer’s patients to get ADHD drugs in world-leading trial – studies suggest pills could tackle dementia symptoms”.